Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PLATO and immunotherapy trials in anal cancer

David Sebag-Montefiore • 18 Nov 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer
CORINTH PLATO

David Sebag-Montefiore, MRCP, FRCR, Leeds Teaching Hospitals NHS Trust, Leeds, UK, talks about two different trials with strategies for improving outcomes from anal cancer treatment; amending dosage of radiotherapy (PLATO; ISRCTN88455282) and novel agent combinations (CORINTH; NCT04046133). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from David Sebag-Montefiore

4:30
The UK approach to proton beam therapy clinical trials
David Sebag-Montefiore • 7 Nov 2019
2:29
MRI and MR-LINAC guided radiotherapy
David Sebag-Montefiore • 14 Jun 2018
2:48
Positive findings of the FOXTROT and RAPIDO trials
David Sebag-Montefiore • 27 Jan 2017
3:46
Overview of RAPIDO trial in rectal cancer and FOxTROT trial in colon cancer
David Sebag-Montefiore • 27 Jan 2017

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals